

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054965 A1

(51) International Patent Classification⁷: **C07C 235/42**,
235/12, 271/22, 271/54, A61K 31/325, 31/16, A61P 29/00

(74) Agent: **BARCIELLI, Giovanna**; Nicox Research Institute Srl, Patent Department, Via L. Ariosto, 21, I-20091 Bresso (Milano) (IT).

(21) International Application Number:
PCT/EP2003/050932

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 December 2003 (03.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2002A002658
17 December 2002 (17.12.2002) IT

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **NICOX S.A.** [FR/FR]; 2455 Routes des Dolines, Batiment I- Espace Gaia II, F-06906 Sophia Antipolis (FR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ONGINI, Ennio** [IT/IT]; Via Fratelli Cervi, Residenza Sorgente, I-20090 Segrate (Milan) (IT). **ALMIRANTE, Nicoletta** [IT/IT]; Via Caracciolo, 26, I-20155 Milano (IT). **DEL SOLDATO, Piero** [IT/IT]; Via E. Toti, 22, I-20152 Monza (Milano) (IT).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DRUGS FOR CHRONIC PAIN

(57) Abstract: The present invention relates to nitrooxyderivatives or salts thereof having the following general formula (I): $R-NR_{1c}-(K)_{k0}-(B)_{b0}-(C)_{c0}-NO_2$ (I), wherein $c0$, $b0$ and $k0$ are 0 or 1; R is the radical of an analgesic drug for chronic pain, for instance neurophatic pain; R_{1c} , is H or alkyl with from 1 to 5 carbon atoms; B is such that its precursor is selected from amino acids, hydroxy acids, polyalcohol, compounds; C is a bivalent radical containing an aliphatic, heterocyclic or aromatic radical.

WO 2004/054965 A1

10/537439

JC17 Rec'd PCT/PTO 03 JUN 2005

"Drugs for chronic pain"

The present invention relates to compounds having an improved effectiveness in
5 reducing the chronic pain, specifically the neurophatic pain. In order to describe chronic
pain, for simplicity always reference to neuropathic pain will be made.

It is known that neurophatic pain is a form of chronic pain arising from a damage
or disease of the central or peripheral nervous system. Neurophatic pain comprises a
series of painful symptomatology such as diabetic neurophatic pain, painful post-
10 infarct syndrome, pain caused by chemotherapeutic treatment or pain arising from
infections by viral agents, for example herpes, for instance Herpes zoster, etc.

Neurophatic pain generally affects patients for many years, and is a social
problem in that symptoms chronicity induces in subjects serious psychological stress.

In last twenty years, research on neurophatic pain pathogenesis has achieved
15 notable advances. Studies carried out on human and animal experimental models of
neurophatic pain have shown that central nervous system reacts to algogen stimuli with
a series of biochemical and physiopathologic responses. This ability of the central
nervous system to functionally and morphologically adapt to algogen stimuli is known
as neuroplasticity and plays an essential role in inducing onset or in maintaining the
20 painful symptomatology.

The usual analgesic drugs actually employed for treating chronic pain are
partially or absolutely not effective.


Carbamazepine, that has been widely used in clinical studies, has shown to be
active in treating trigeminal neuralgia, diabetic neurophatic pain, and post-herpetic
25 neuralgia. The administration of this drug has the drawback to present side effects such
as somnolence, dizziness, ataxy, nausea and vomiting, thus limiting its use.

In last years, further drugs for the treatment of neuropathic pain have been tested.
Among these in particular gabapentin can be mentioned, that is very active as analgesic
drug for treating neurophatic pain, mainly against diabetic neurophatic pain and post-
30 herpetic pain. However, also in this case serious adverse effects have been observed, for
example somnolence, weariness, obesity, etc. (Martindale XXXth Ed, page 374).

It was thus object of the present invention to provide drugs having an improved pharmacotherapeutic profile and/or lower side effects in the treatment of chronic pain, in particular neurophatic pain.

It has been now surprisingly and unexpectedly found from the Applicant that this
5 problem can be solved with the class of drugs described below.

The present invention relates to nitrooxyderivatives or salts thereof having the following general formula (I):



wherein

10 c_0 is 0 or 1, preferably 1;


b_0 is 0 or 1, with the proviso that c_0 and b_0 can not be simultaneously 0;

k_0 is 0 or 1;

R is the radical of an analgesic drug for chronic pain, for instance neurophatic pain;

R_{1c} being H or straight or branched alkyl with from 1 to 5 carbon atoms;

15 K is (CO) or the bivalent radical (1C) having the following formula:



wherein the carbonyl group is bound to T_1 ; R_t and R'_t , same or different, are H, C_1 - C_{10} -alkyl, phenyl or benzyl, $-COOR_y$, in which R_y = H, C_1 - C_{10} -alkyl, phenyl, benzyl;

$B = -T_B-X_2-T_{BI}$ wherein

20 $T_B = (CO)$ or X, in which X = O, S, NH;

with the proviso that:

when $b_0 = 1$ and $k_0 = 0$, then $T_B = (CO)$;


when $b_0 = 1$ and $k_0 = 1$, being K = (CO), then $T_B = X$ as defined above;

$T_{BI} = (CO)$ or (X), wherein X is as defined above;


25 when $c_0 = 0$, then $T_{BI} = -O-$;

X_2 is such a bivalent bridging group such as the corresponding precursor of B, having the formula $Z-T_B-X_2-T_{BI}-Z'$ in which Z, Z' are independently H or OH, is selected from the following compounds:


- Aminoacids: L-carnosine (CI), penicillamine (CV), N-acetylpenicillamine (CVI),
30 cysteine (CVII), N-acetylcysteine (CVIII):




(CI)




(CV)



(CVI)




(CVII)




(CVIII)

5


- Hydroxyacids: gallic acid (DI), ferulic acid (DII), gentisic acid (DIII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII), vanillic acid (DVIII), syringic acid (DXI):




(DII)




(DI)




(DIII)




(DV)




(DVI)



(DVII)




(DVIII)



(DXI)

10

- aromatic polyalcohols: hydroquinone (EVIII), methoxyhydroquinone (EXI), hydroxyhydroquinone (EXII), coniferyl alcohol (EXXXII), 4-hydroxyphenetyl alcohol (EXXXIII), p-coumaric alcohol (EXXXIV):




10 C = bivalent radical having the formula $-T_c-Y-$
wherein

$T_c = (CO)$ or X being as defined above;

with the proviso that when $b_0 = 0$ and $k_0 = 1$:

- $T_c = (CO)$ when $K = (1C)$,
- 15 - $T_c = X$ as defined above when $K = (CO)$;

Y has one of the following meanings:



wherein:

nIX is an integer of from 0 to 5, preferably from 1;


25 $nIIX$ is an integer of from 1 to 5, preferably from 1;

R_{TIX} , R_{TIX} , R_{TIX} , R_{TIX} , the same or different, are H or straight or branched C_1 - C_4 -alkyl; preferably R_{TIX} , R_{TIX} , R_{TIX} , R_{TIX} are H;


Y^3 is a saturated, unsaturated or aromatic heterocyclic ring with 5 or 6 atoms, containing one to three heteroatoms, preferably one or two, said heteroatoms being the same or different and selected from nitrogen, oxygen or sulphur;

or Y may be:


- 5 an alkyleneoxy group $-R'O-$ in which R' is straight or branched C_1-C_{20} , preferably with from 2 to 6 carbon atoms, or a cycloalkylene with from 5 to 7 carbon atoms, and wherein in cycloalkylene ring one or more carbon atoms can be replaced by heteroatoms and the ring may present side chains of R' type, R' being as defined above; or one of the following groups:




wherein nf is an integer from 1 to 6, preferably from 1 to 4;



wherein $R_{1f} = H, CH_3$ and nf is an integer from 1 to 6, preferably from 1 to 4;




- 15 wherein $n3$ is an integer from 0 to 5 and $n3'$ is an integer from 1 to 3; or



in which $n3$ and $n3'$ have the meaning mentioned above.

- Radical R in formula (I) is preferably a radical of chronic analgesic drugs, in particular drugs for neurophatic pain, and it can be selected from the usual products available on the market for said use. The tricyclic antidepressant and antiepileptic drugs can be mentioned.
- 20

R is the radical of an analgesic drug having formula (II):



wherein:

W is a carbon or nitrogen atom;

m is an integer of from 0 to 2;


5 $R_0 = H, -(CH_2)_n-COOR_y$, R_y being as defined above;

n is an integer of from 0 to 2;

$R_1 = H$; when $W = N$, R_1 is the electronic doublet on nitrogen atom (free valence);

R_2 is selected from the following groups:

- phenyl, optionally substituted with a halogen atom or with a group selected from
10 $-OCH_3$, $-CF_3$, nitro;
- mono or dihydroxy-substituted benzyl, preferably 3,4-dihydroxybenzyl;
- amidino group: $H_2N(C=NH)-$;
- a radical of formula (IIA), wherein optionally an ethylenic unsaturation may be present between the carbon atoms in position 1 and 2, or 3 and 4 or 4 and 5:



15 wherein:

p, p_1 , p_2 are integers, same or different, and are 0 or 1;

p_3 is an integer of from 0 to 10;

R_4 is hydrogen, straight or branched C_1 - C_6 -alkyl, free valence;

20 R_5 may have the following meanings:

- hydrogen,
- straight or branched C_1 - C_6 -alkyl,
- C_3 - C_6 -cycloalkyl,
- OR_A , R_A having the following meanings:

- straight or branched C₁-C₆-alkyl, optionally substituted with one or more halogen atoms, preferably F,
 - phenyl optionally substituted with a halogen atom or with one of the following groups: -OCH₃, -CF₃, nitro;
- 5 R₆, R_{6A}, R₇, R₈, the same or different, are H, methyl or free valence, with the proviso that when an ethylenic unsaturation is present between C₁ and C₂ in radical of formula (IIA), R₄ and R₅ are free valences able to form the double bond between C₁ and C₂; if the unsaturation is between C₃ and C₄, R₆ and R₇ are free valence able to form the double bond between C₃ and C₄; if the unsaturation is between C₄ and
- 10 C₅, R₇ and R₈ are free valence able to form the double bond between C₄ and C₅;
- Q is H, OH, OR_B, R_B being benzyl, straight or branched C₁-C₆-alkyl, optionally substituted with one or more halogen atoms, preferably F, phenyl optionally substituted with a halogen atom or with one of the following groups: -OCH₃, -CF₃, nitro;
- 15 or Q may have one of the following meanings:
- straight or branched C₁-C₆-alkyl,
 - C₃-C₆-cycloalkyl,
 - guanidino (H₂NC(=NH)NH-),
 - thioguanidino (H₂NC(=S)NH-);
- 20 in formula (II) R₂ with R₁ and with W = C form together a C₄-C₁₀ saturated or unsaturated ring, preferably a C₆ saturated one.
- When in formula (II) W = C, m = 1 and R₀ = -(CH₂)_n-COOR_y, wherein n = 1 and R_y = H; R₂ and R₁ with W as defined above form the cyclohexane ring; the drug precursor of R having the formula R-NH₂ is known as gabapentin;
- 25 when in formula (II) W = C, m = 0 and R₀ is defined as for gabapentin with n = 0; R₁ = H; R₂ is the radical of formula (IIA) in which p = p₁ = 1, p₂ = p₃ = 0, R₄ = R₅ = R₆ = R_{6A} = H, Q = H; the drug precursor of R having the formula R-NH₂ is known as norvaline;
- when in formula (II) W = C, m = 0 and R₀ is defined as for gabapentin with n = 0;
- 30 R₁ = H; R₂ is the radical of formula (IIA) in which p = p₁ = 1, p₂ = p₃ = 0, R₄ = R₅ = R₆ = R_{6A} = H, Q is the guanidino group; the drug precursor of R having the formula R-NH₂ is known as arginine;

when in formula (II) $W = C$, $m = 0$ and R_0 if defined as for gabapentin with $n = 0$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = 1$, $p_2 = p_3 = 0$, $R_4 = R_5 = R_6 = R_{6A} = H$, Q is the thioguanidino group; the drug precursor of R having the formula $R-NH_2$ is known as thiocitrulline;

5 when in formula (II) $W = C$, $m = 1$ and R_0 if defined as for gabapentin with $n = 1$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = p_2 = p_3 = 0$, $R_4 = H$, $R_5 = Q = CH_3$; the drug precursor of R having the formula $R-NH_2$ is known as pregabalin;

when in formula (II) $W = C$ and has (S) configuration, $m = 1$ and R_0 if defined as for gabapentin with $n = 1$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = p_2 = p_3 = 0$, $R_4 = H$, $R_5 = Q = CH_3$; the drug precursor of R having the formula $R-NH_2$ is known as (S)-3-isobutylGABA;

when in formula (II) $W = C$ and has (S), $m = 0$; $R_0 = R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = 1$, $p_2 = p_3 = 0$, $R_4 = R_5 = R_6 = R_{6A} = H$, Q is the guanidino group; the drug precursor of R having the formula $R-NH_2$ is known as agmatine;

when in formula (II) $W = C$, $m = 0$; R_0 if defined as for gabapentin with $n = 2$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = p_2 = p_3 = 0$, R_4 and R_5 are free valences and between C_1 and C_2 there is an ethylenic unsaturation, $Q = H$; the drug precursor of R having the formula $R-NH_2$ is known as vigabatrin;


20 when in formula (II) $W = C$, $m = 0$; R_0 if defined as for gabapentin with $n = 0$; $R_1 = H$; R_2 is the 3,4-dihydroxybenzyl radical; the drug precursor of R having the formula $R-NH_2$ is known as 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid (dopa).

Further compounds employed for chronic pain and that can be used as precursors of R in formula (I) are lamotrigine, topiramate, zonisamide, carbamazepine, felbamate, amineptine, amoxapine, demexiptiline, desipramine, nortriptyline, tianeptine.


Generally, the drug precursors of R are synthesized according to the procedures described in "The Merck Index, 12th Ed." (1996). When the drug precursors of R present in the molecule the radical of formula (IIA), they can be obtained as described in WO 00/79658.

30 The precursor compounds of B falling within the groups mentioned above can be synthesized according to methods well known in literature and mentioned for example in "The Merck Index, 12th Ed.", here incorporated in full for reference.


In formula (III), Y^3 is selected from the following bivalent radicals:




(Y1) (Y2) (Y3) (Y4) (Y5) (Y6)



5 (Y19)



(Y7) (Y8) (Y9) (Y10) (Y11) (Y18)



(Y12) (Y13) (Y14) (Y15) (Y16) (Y17)

10


Preferred among the Y^3 meanings are the following: (Y12), having both the free valences in ortho position as to the nitrogen atom; (Y16) with both the valences attached to the heteroatoms, Y1 (pyrazole) 3,5-disubstituted.

15 The Y precursors as defined by formula (III), in which the oxygen free valence is saturated with H and the endstanding carbon atom free valence is saturated with a carboxylic or hydroxylic group, are products available on the market or they can be obtained according to well known procedures.

20 In formula (I), the B precursors preferred for synthesizing the nitrooxyderivatives to be employed in the present invention are the following: ferulic acid and N-acetylcysteine, the preferred drug precursors being gabapentin, norvaline, arginine, pregabalin, (S)-3-isobutylGABA, agmatine and vigabatrin.

The preferred compounds of formula (I) of the present invention are the following:


1-[4-(nitrooxymethyl)benzoylaminoethyl]-cyclohexaneacetic acid (XVA),



5


(XVA)

1-[3-(nitrooxymethyl)benzoylaminoethyl]-cyclohexaneacetic acid (XVIA),



(XVIA)


1-[2-(nitrooxymethyl)benzoylaminoethyl]-cyclohexaneacetic acid (XVIIA),



10


(XVIIA)

1-(4-nitrooxybutanoylaminoethyl)-cyclohexaneacetic acid (XVIII A),




(XVIII A)

15 1-(nitrooxymethoxycarbonylaminoethyl)-cyclohexaneacetic acid (XIXA),



(XIXA)


1-{[4-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminoethyl}-cyclohexaneacetic acid (XXA),



5

(XXA)


1-{[3-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminoethyl}-cyclohexaneacetic acid (XXIA),



10


(XXIA)

1-{[2-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminoethyl}-cyclohexaneacetic acid (XXIIA),




(XXIIA)

1-[3-(nitrooxymethyl)phenoxy]carbonylaminoethyl]-cyclohexaneacetic acid (XXIII A),




(XXIII A)

5 {2-methoxy-4-[(1E)-3-[4-(nitrooxybutoxy)-3-oxa-1-propenyl]phenoxy]-carbonylaminoethyl]-cyclohexaneacetic acid (XXIV A),




(XXIV A)

3-(S)-[4-(nitrooxymethyl)benzoylaminoethyl]-5-methyl-hexanoic acid (XXV A),




(XXV A)

3-(S)-[3-(nitrooxymethyl)benzoylaminoethyl]-5-methyl-hexanoic acid (XXVI A),




(XXVI A)

3(S)-[2-(nitrooxymethyl)benzoylaminomethyl]-5-methyl-hexanoic acid (XXVIIA),




(XXVIIA)

3(S)-[4-(nitrooxybutanoyl)aminomethyl]-5-methyl-hexanoic acid (XXVIII A),




(XXVIII A)

3(S)-[4-(nitrooxymethoxycarbonyl)aminomethyl]-5-methyl-hexanoic acid (XXIX A),




(XXIX A)

10 3(S)-{[2-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-5-methyl-hexanoic acid (XXXA),




(XXXA)

3(S)-{[3-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-5-methyl-hexanoic acid (XXXIA),




(XXXIA)

5 3(S)-[4-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-5-methyl-hexanoic acid (XXXIIA),




(XXXIIA)

10 3(S)-[(3-nitrooxymethyl)phenoxy]carbonylaminomethyl]-5-methyl-hexanoic acid (XXXIIIA),




(XXXIIIA)

3(S)-{2-methoxy-4-[(1E)-3-[4-(nitrooxybutoxy)-3-oxa-1-propenyl]phenoxy]carbonylaminomethyl}-5-methyl-hexanoic acid (XXXIVA),



(XXXIVA)

1-[4-(nitrooxybutyloxycarbonyl)aminomethyl]-cyclohexaneacetic acid (XXXVA),



(XXXVA)

5

The compounds of the invention can be used also in form of the corresponding salts with pharmacologically acceptable cations, such as the salts of alkali metals.

Having a salifiable nitrogen atom within their molecule, for example when in formula (I) $c_0 = 1$ and Y = moiety of formula (III), the compounds of the present invention can be transformed into the corresponding salts by reaction in an organic solvent, such as acetonitrile, tetrahydrofuran, with an equimolar amount of a corresponding organic or inorganic acid. Examples of organic acid are oxalic, tartaric, maleic, succinic and citric acids. Examples of inorganic acids are nitric, hydrochloric sulphuric and phosphoric acids. Preferred are the nitrate salts.

The compounds of the invention have shown to possess an improved activity for treatment of the chronic pain, in particular neurophatic pain, both as central and peripheric nervous system is concerned. Moreover, it has been surprisingly found that the compounds of the invention have an improved effect not only reducing neurophatic pain, but also showing unexpectedly a check on pathologic condition progress inducing neurophatic pain. When for example the drugs of the present invention are administered

to diabetic subjects for diabetic neuropathic pain therapy, it has been found that said compound are able not only to reduce neuropathies, but also to lower diabetes induced complications, for example on blood vessels and/or renal apparatus.

The compounds of the present invention are in particular effective in treating
5 neuropathic pain, for example diabetic neuropathic pain and post-infarct pain.

The compounds of the invention can be also employed in combination or in admixture with well known NO-donors. Said compounds contain for example one or more ONO₂ or ONO groups within their molecule.

NO -donors that may be used in association with the invention compounds should
10 meet the in vitro test described here below. This text relates the generation of nitric oxide by NO-donors when in presence of endothelial cells (method a) or platelets (method b), for example nitro-glycerine, nicorandil, nitroprussiate, etc.

a) Endothelial cells

Plated human umbilical vein cells with density of 10³ cells/well, have been incubated 5
15 minutes with NO-donor scalar concentrations (1-100 µg/ml). Incubation medium (physiological solvent, i.e. Tyrode) has been then analysed to ascertain the ability to generate NO by means of:

- 1) nitric oxide detection by chemiluminescence,
- 2) cGMP determination (cyclic GMP No. 2715 of Merck Index mentioned above).

20 As far as chemiluminescence analysis is concerned, a 100 µl aliquot has been injected into reaction chamber of an chemiluminescence analyzer containing glacial acetic acid and potassium iodide. The nitrites/nitrates present in medium in said conditions are converted in NO which is then revealed owing to its reaction with ozone, with consequent light production. As usual in devices measuring chemiluminescence,
25 the produced luminescence is directly proportional to the generated NO levels and can be measured by means of the suitable photomultiplier unity of an chemiluminescence analyzer. The photomultiplier turns incident light into electric voltage, that then is quantitatively registered. Referring to a calibration curve, obtained with scalar nitrite concentrations, it has been possible to quantitatively evaluate the concentration of the
30 generated NO. For example, from incubation of 100 µl nicorandil, an amount of about 10 µM NO was generated.

In order to determine cGMP, an amount of incubation medium (100 µl) was centrifuged 20 s at 1000 rpm. Supernatant was discarded and the sediment was treated

with frozen phosphate buffer (pH 7.4). The cGMP produced levels were evaluated by immunoenzyme assay with specific reagents. From these experiments it results that in said experimental conditions the incubation with one of the several tested NO-donors caused a notable cGMP increase in comparison with the values obtained in absence of a NO-donor. For example, after incubation with 100 μ M sodium nitroprussiate a 20 fold increase was registered in comparison with the corresponding value obtained incubating the vehicle alone without NO-donor.

b) Platelets

Washed human platelets have been used, obtained as described by Radomski et al., (Br. J. Pharmacol. 92, 639-1987). Amounts of 0.4 ml were incubated 5 minutes with scalar NO -donor concentrations (1-100 μ g/ml). The incubation medium (i.e. Tyrode) was then analysed in order to determine the ability to generate NO by revealing nitric oxide with chemiluminescence technique and cGMP determination using the procedure previously described for the analysis carried out on endothelial cells. As to the chemiluminescence assay, also in this case on the basis of a calibration curve plotted with nitrite scalar concentrations, it has been possible to quantitatively define the concentration of the generated NO. For example, after incubation of 100 μ M nicorandil, an amount of 35 μ M of NO was generated.

For determining cGMP, also in these experimental conditions it resulted that the incubation with one of the several tested NO-donors caused a notable cGMP increase in comparison with the values obtained in absence of a NO-donor. For example, after incubation with 100 μ M sodium nitroprussiate a 30 fold increase was registered in comparison with the value obtained incubating the vehicle alone without NO-donor.

The preferred NO-donors are those containing within the molecule radicals of the following drugs: aspirin, salicylic acid, ibuprofen, paracetamol, naproxen, diclofenac, flurbiprofen. These preferred compounds are synthesized as described in patent applications WO 95/20641, WO 97/16405, WO 95/09831, WO 01/12584.

The compounds of the invention can be obtained according to the synthesis procedures described here below.

Generally, should in the drug molecule several reactive groups be present, such as COOH and/or HX, wherein X is O, S or NH, they can be protected before the reaction according to the procedures known from literature, for example as described by Th. W. Greene in "Protective Groups In Organic Synthesis", Harvard University Press, 1980.

However, protection of these groups is not strictly necessary for obtaining the compounds of the present invention.

For preparing the compounds of the present invention, when $k_0 = 0$ the analgesic drug amine function was reacted with a reactive compound of linker C precursor, if $b_0 = 0$, or of linker B precursor when $b_0 = 1$.

When in formula (I) $b_0 = 0$, the analgesic drug was generally reacted with one of the following compounds:

1. if $k_0 = 0$ and the binding function with the analgesic drug is an amide function, the compound reacting with the drug was obtained as follows.

Starting compounds are acyl halides of formula $\text{Hal-Y}_1\text{-CO-Hal}$, wherein Y_1 is Y as defined above but without the oxygen atom binding NO_2 and $\text{Hal} = \text{Cl, Br, I}$. These compounds, when not available on the market, may be obtained according to a process well known in the art, for example from corresponding acids with thionyl or oxalyl chloride, P^{III} or P^{IV} halides, in solvents inert at the reaction conditions such as toluene, chloroform, DMF etc.


The acyl halide having the formula reported above, was reacted with a carboxylic group condensing agent, such as N-hydroxysuccinimide (SIMD-N-OH) according to methods known from the art, for example in halogenated solvents in the presence of a base at room temperature, obtaining N-hydroxysuccinimide ester as illustrated in the following reaction scheme:




1a. The hydroxysuccinimide ester was reacted with the amine function of the analgesic drug at room temperature in alcoholic and/or chlorinated solvents, in presence of an organic or inorganic base according to the following scheme:



1-1. Alternatively, instead of employing the above mentioned acyl halides, hydroxy acids can be used having the formula $\text{HO-Y}_1\text{-COOH}$, wherein Y_1 is as defined above, that were reacted with N-hydroxysuccinimide in presence of an agent activating the carboxylic group, such as DCC, in halogenated solvents at room temperature according to the following scheme:




1-1.a The compound obtained in 1-1 was reacted with the amine function of the analgesic drug at the conditions mentioned in 1a according to the following scheme:




1b. When in formula (I), $k_0 = 1$ with $K = \text{CO}$, the bond function with the analgesic drug is a carbamic function. Drug RNR_{1c}H was reacted with an halogenformiate of formula $\text{Hal-Y}_1\text{-OCO-Hal}$, wherein Y_1 is as defined above.

5 Generally, the employed halogenformiate is available on the market or it can be obtained from the corresponding alcohols by reaction with triphosgene in presence of an organic base according to methods well known from the art. The reaction of halogenformiate with drug is carried out in a solvent mixture at room temperature and in presence of a base, for example in water and dioxane or methylene chloride and
10 DMF. The reaction scheme is the following:



1c. Preparation of nitrooxyderivatives from amides and carbamates obtained with the procedures mentioned above ($b_0 = 0$)

When compounds obtained with the reaction described above have the formula $\text{R-NR}_{1c}\text{-CO-Y}_1\text{-Hal}$ (2A) or $\text{R-NR}_{1c}\text{-CO-O-Y}_1\text{-Hal}$ (2C), the corresponding
15 nitrooxyderivatives have been prepared reacting (2A) or (2C) with AgNO_3 in an organic solvent such as acetonitrile, tetrahydrofuran, at a temperature of from 20° to 100°C according to the scheme:



When compounds obtained with the reactions described above have the formula $\text{R-NR}_{1c}\text{-CO-Y}_1\text{-OH}$ (2B), the hydroxyl group was subjected to halogenation, for example with PBr_3 , PCl_5 , SOCl_2 , $\text{PPh}_3 + \text{I}_2$ at room temperature, then it was reacted with AgNO_3 in an organic solvent, such as acetonitrile, tetrahydrofuran at the conditions
25 mentioned above. Nitrooxyderivatives having the formula $\text{R-NR}_{1c}\text{-CO-Y}_1\text{-NO}_2$ were obtained.



1d. When in formula (I), $b_0 = 0$, $k_0 = 1$ and for example $K = (1\text{C})$, the following steps were performed. The amine function of the drug was reacted with the commercially available chloromethyl chloroformiate $\text{ClC(O)OCH}_2\text{Cl}$. The compound $\text{R-NR}_{1c}\text{-(CO)-OCH}_2\text{Cl}$ thus obtained was redacted with $\text{HO-Y}_1\text{-COOH}$ in basic medium as indicated
30 in 1a to give a compound of formula $\text{R-NR}_{1c}\text{-K-(CO)-Y}_1\text{-OH}$, that was then reacted as above in 1c to give the corresponding nitrooxyderivative.

2. When in formula (I), $b_0 = c_0 = 1$, the synthesis to give the corresponding nitroxyderivatives involves three steps. In first step, amides (in formula (I) $k_0 = 0$) having substituents containing Hal groups (Hal = Cl, Br, I) or carbamates (in formula (I) $k_0 = 1$) having substituents containing Hal groups as specified below were obtained.

5 2a. For preparing halogen-substituted amides, the amine function of the drug was reacted with a N-hydroxysuccinimide ester obtained from an acyl halide of formula $P-X_2-COHal$, wherein:


- X_2 and Hal are as defined above,
- $P = HX$ in which X is as defined above or a carboxylic group protected for example with the corresponding tert-butyl ester ,

10 with N-hydroxysuccinimide (SIMD-N-OH) according to methods known in the art, for example at room temperature in halogenated solvents, in presence of a base, to give the compound of formula $R-NR_{1c}-CO-X_2-P$ that, when $P = HX$, was reacted with a compound of formula $Hal-Y_1-CO-Hal$ wherein Hal and Y_1 are as defined above. The reaction scheme is reported here below:



20 When in formula (3A) $P =$ ester group as defined above, the carboxylic function can be restored with known procedures, for example reacting with anhydrous HCl in ethyl acetate or dioxane if the starting ester is tert-butyl ester. The acid thus obtained was reacted with a halogenated alcohol of formula $Hal-Y_1-OH$. The halogenated alcohol are available on the market.

25 2a.1 Alternatively, the drug $RNR_{1c}H$ was reacted with a N-hydroxysuccinimide ester, obtained from an acid of formula $P-X_2-COOH$, wherein P and X_2 are defined above, and N-hydroxysuccinimide (SIMD-N-OH), in presence of dicyclohexylcarbodiimide or another condensing agent according to methods well known in the art, for example at room temperature in halogenated solvents to give compound $R-NR_{1c}-CO-X_2-P$ (3A) as for the following scheme:



Compound of formula (3A) was then reacted as described in 2a to give (3A').

2b. Preparation of halogen-substituted carbamates

From compound Hal-Y₁-O-CO-X₂-XH (4A) and triphosgene in presence of an organic base a halogenformiate of formula Hal-Y₁-O-CO-X₂-XCO-Hal was prepared according to the scheme reported in 1b. Compound (4A) was obtained reacting an alcohol of formula Hal-Y₁-OH with HX-X₂-COOH. The halogenformiate thus obtained
 5 was reacted with the drug amine function according to well known procedures, for example in DMF and/or methylene chloride in presence of a base at room temperature as for the following scheme:



2c. Preparation of nitrooxyderivatives from amides and carbamates obtained in 2a or 2b.

- 10 Compounds (3A') or (3B) react in an organic solvent, such as acetonitrile, tetrahydrofuran, through end standing halogen with AgNO₃ to give the corresponding nitrooxyderivatives.

Applicant has surprisingly and unexpectedly found that compounds of the present invention show a higher activity on chronic pain than the corresponding precursors.

- 15 When compounds of the present invention contain one or more chiral centres, they can be employed in racemic form, as diastereomer or enantiomer mixture, as pure enantiomers or diastereomers. Should the compounds have geometric asymmetry, said compounds can be used in cis or trans form.

- The compounds of the present invention are formulated in the corresponding
 20 pharmaceutical compositions for oral, parenteral and topic administration according to techniques well known in the art with usual excipients: for example as described in "Remington's Pharmaceutical Sciences 15th Ed."

- The amount on molar basis of the active ingredient in these compositions is equal or lower then the maximal amount expected for precursor drugs. Due to the excellent
 25 tolerability, higher doses can also be employed. The daily doses to be administered are those of the precursor drugs or eventually lower. Said daily doses can be found for example in "Physician's Desk Reference".

The following examples are to further illustrate but not limit the scope of the present invention.

EXAMPLES

EXAMPLE 1

Synthesis of 1-[4-(nitrooxymethyl)benzoylaminomethyl]cyclohexaneacetic acid (formula XVA)

5 A) Synthesis of N-hydroxysuccinimidyl 4-(chloromethyl)benzoate

To a solution of N-hydroxysuccinimide (1.375g, 11.94 mmol) in methylene chloride (30 ml) triethylamine was added (1.66 ml, 11.94 mmol). To the solution thus obtained, cooled in a water/ice bath, slowly a solution of 4-(chloromethyl)benzoyl chloride (2.26 g, 11.94 mmol) in methylene chloride (20 ml) was added. When the
10 adding was over, the mixture was allowed to stand overnight at room temperature. The mixture was then dried under vacuum to give 4.84 g of a white solid (mixture of the desired compound and triethylammonium chloride with quantitative yield) that was employed in the next reaction without further purification.

B) Synthesis of 1-[4-(chloromethyl)benzoylaminomethyl]cyclohexaneacetic acid

15 To a suspension of 1-(aminomethyl)cyclohexaneacetic acid (gabapentin, 2.25 g, 13.13 mmol) in absolute ethanol (100 ml) triethylamine was added (3.66 ml, 26.27 mmol) to give a clear solution. In the solution thus obtained and cooled in a water/ice bath, a solution of the equimolar mixture of triethylammonium chloride and N-hydroxysuccinimidyl 4-(chloromethyl)benzoate (4.84 g, 11.94 mmol) in methylene
20 chloride (100 ml) obtained in A) was dropped. After stirring about 4 hours at room temperature, to the mixture ethyl acetate was added (100 ml) and the solution was extracted with a 4% water solution of hydrochloric acid. The organic phase was dried under vacuum to give 3.85 g of the desired product as a white solid.

C) Synthesis of 1-[4-(nitrooxymethyl)benzoylaminomethyl]cyclohexaneacetic acid

25 To a suspension of 1-[4-(chloromethyl)benzoylaminomethyl]cyclohexaneacetic acid (4.01 g, 12.39 mmol) in acetonitrile (250 ml) silver nitrate was added (2.11 g, 12.39 mmol). The mixture was stirred at 60°C under vacuum out of light adding silver nitrate in five aliquots within about 20 hours. The mixture was heated for 24 hours, adding other 5 equivalents of the silver nitrate further to those already added. The salt
30 thus formed was filtered off, to the mixture ethyl acetate (200 ml) and a 2% hydrochloric acid solution were added. The precipitated insoluble salts were filtered off and the organic phase was dried under vacuum. The raw material thus obtained was purified by silica gel chromatography with n-hexane/ethyl acetate 6/4 (v/v) as eluent.

The product thus obtained was crystallized from ethyl acetate/n-hexane to give 2.45 g of a white solid with m.p = 127-128°C.

¹H-NMR (CDCl₃) ppm: 7.86 (2H, d); 7.50 (2H, d); 7.06 (1H, t); 5.49 (2H, s); 3.54 (2H, d); 2.43 (2H, s); 1.53 (10H, m).

5

EXAMPLE 2

Synthesis of 1-(nitrooxymethoxycarbonylaminomethyl)cyclohexaneacetic acid (formula XIXA)

A) Synthesis of 1-(chloromethoxycarbonylaminomethyl)cyclohexaneacetic acid

10 To a solution of 1-(aminomethyl)cyclohexaneacetic acid (gabapentin, 2.00 g, 11.68 mmol) in a water (30 ml) and dioxane (20 ml) mixture, diisopropylethylamine was added (4.06 ml, 23.36 mmol). In the solution thus obtained, and cooled in a water/ice bath, chloromethyl chloroformate (1.25 ml, 14.02 mmol) dissolved in dioxane (20 ml) was slowly dropped. At the end of adding, the mixture was allowed to
15 stand 3 hours at room temperature. The mixture was then poured in a 4% hydrochloric acid solution to sink the end pH value to about 2. Ethyl acetate was added and the organic phase was dried under vacuum to give 2.87 g of a clear, yellow oil that was employed in the next reaction without further purification.

B) Synthesis of 1-(nitrooxymethoxycarbonylaminomethyl)cyclohexaneacetic acid

20 To a solution of 1-(chloromethoxycarbonylaminomethyl)cyclohexaneacetic acid (2.87 g, 10.92 mmol) in acetonitrile (25 ml) silver nitrate was added (3.71 g, 21.84 mmol). The mixture was stirred 3 hours under vacuum out of light at 40°C. The precipitated salt was filtered off and to the mixture ethyl acetate (30 ml) and a 2% hydrochloric acid solution were added. The salts thus formed was removed by filtration
25 and the organic phase was dried under vacuum. The oily product thus obtained was purified by silica gel chromatography with n-hexane/ethyl acetate 6/4 (v/v) as eluent to give 2.68 g of colourless oil,

¹H-NMR (CDCl₃) ppm: 6.03 (2H, s); 5.51 (1H, t); 3.30 (2H d), 2.36 (2H, s); 1.47 (10H, m).

30

EXAMPLE 3

Synthesis of 1-[3-(nitrooxymethyl)phenoxy carbonylaminomethyl]cyclohexaneacetic acid (formula XXIIIA)

A) Synthesis of 1-[3-(bromomethyl)phenoxy]carbonylaminomethyl)cyclohexanecarboxylic acid

To a suspension of 3-bromomethylphenol (0.50 g, 2.67 mmol) in methylene chloride (8 ml), bis(trichloromethyl) carbonate (triphosgene, 0.368 g, 1.24 mmol) dissolved in methyl chloride (2 ml) and diisopropylethylamine (0.466 ml, 2.67 mmol) were cool added. The solution thus obtained was stirred one night at room temperature and then refluxed for 2 hours. This cooled solution was then dropped in a suspension of 1-(aminomethyl)cyclohexanecarboxylic acid (gabapentin, 0.911 g, 5.35 mmol) and diisopropylethylamine (0.932 ml, 5.35 mmol) in anhydrous dimethylformamide (4 ml). After 3 hours stirring, to the mixture ethyl acetate was added and it was washed with a 4% hydrochloric acid solution. The organic phase was dried under vacuum and the raw product thus obtained was purified by silica gel chromatography with n-hexane/ethyl acetate 1/1 (v/v) as eluent. The desired product was obtained as an oil (0.100 g) that was employed without further purification.

B) Synthesis of 1-[3-(nitrooxymethyl)phenoxy]carbonylaminomethyl)cyclohexanecarboxylic acid

To a suspension of 1-[3-(bromomethyl)phenoxy]carbonylaminomethyl)cyclohexanecarboxylic acid (0.100 g, 0.26 mmol) in acetonitrile (2 ml) silver nitrate was added (0.100 g, 0.59 mmol). The mixture was stirred overnight at room temperature under nitrogen atmosphere out of light. The salt thus formed was filtered off and to the mixture ethyl acetate (5 ml) and a 2% hydrochloric acid solution were added. Insoluble salts were filtered off and the organic phase was purified by silica gel chromatography with methylene chloride/methanol 97/3 (v/v) as eluent, to give 0.080 g of product as an oil.

¹H-NMR (CDCl₃) ppm: 7.38 (1H, t); 7.22 (3H, m); 5.68 (1H, t); 5.43 (2H, s); 3.34 (2H, d); 2.41 (2H, s); 1.49 (10H, m).

EXAMPLE 4

Synthesis of 1-[4-(nitrooxybutyloxycarbonyl)aminomethyl]cyclohexanecarboxylic acid (formula XXXVA)

A) Synthesis of 1-[4-(chlorobutyloxycarbonyl)aminomethyl]cyclohexanecarboxylic acid

To a solution of 1-(aminomethyl)cyclohexanecarboxylic acid (1.95 g, 11.4 mmol) in dioxane/water (1:1, 40 ml), N,N-diisopropylethylamine was added (4.00 ml, 23.0

mmol) and the solution was cooled at 0°C. Then 1-chlorobutyl chloroformate was slowly added (1.30 ml, 9.50 mmol) and the reaction was allowed to reach room temperature and maintained 5 hours under stirring. The mixture was diluted with methylene chloride and washed with 4% aqueous hydrochloric acid, dehydrated and dried under vacuum, to give 2.87 g of an colourless oil that was employed in the next reaction without further purification.

B) Synthesis of 1-[4-(iodobutyloxycarbonyl)aminomethyl]cyclohexaneacetic acid

To a solution of 1-[4-(chlorobutyloxycarbonyl)aminomethyl]cyclohexaneacetic acid (1.68 g, 5.70 mmol) in acetonitrile (20 ml), sodium iodide was added (8.48 g, 57.0 mmol) and the reaction mixture was refluxed 5 hours under stirring. The solvent was then removed under vacuum and the residue treated with methylene chloride. The organic phase was washed with water, dehydrated and dried under vacuum to give 2.12 g of an oily product that was employed in the next step without purification.

C) Synthesis of 1-[4-(nitrooxybutyloxycarbonyl)aminomethyl]cyclohexaneacetic acid

To a solution of 1-[4-(iodobutyloxycarbonyl)aminomethyl]cyclohexaneacetic acid (2.12 g, 5.30 mmol) in acetonitrile (25 ml), silver nitrate was added (2.42 g, 14.2 mmol). The mixture was stirred 5 hours at 40°C under nitrogen atmosphere and out of light, then it was filtered on celite and concentrated. The residue was treated with methylene chloride and extracted with a 4% hydrochloric acid solution. The salts thus formed were filtered off and the aqueous phase was extracted with methylene chloride. The organic phases were washed with a saturated sodium chloride solution, dehydrated and dried under vacuum. The oily residue was dissolved in ethyl ether, filtered on celite and dried under vacuum to give 1.64 g of an oily product.

¹H-NMR (CDCl₃) ppm: 5.65 (1H, m); 4.49 (2H, t); 4.12 (2H, t); 3.23 (2H, d); 2.34 (2H, s); 1.9-1.7 (4H, m); 1.6-1.3 (10H, m).

EXAMPLE F1

Evaluation of analgesic activity of the compounds of the invention by writhing test (Vinegar et al., 1979).

Nine groups of male Swiss mice (20-25 g, Charles River), 10 animals each, received by oral administration through gastric tube (gavage) gabapentin in an amount of from 1 to 10 mg/kg or the compound of the invention (XVA, Example 1), hereinafter NO-gabapentin, in an amount of from 1 to 10 mg/kg dissolved in saline solution. One

hour after administration of the compound solutions, through intraperitoneal injection the mice received a glacial acetic acid solution (0,5 ml, 0.6%). Within 15 minutes subsequent to the administration of acetic acid, in every animal the number of abdominal contractions was counted. Analysis was carried out in blind.

- 5 The results reported in Table 1 are given as the number of total contractions within the observation time (15 minutes). The results show that NO-gabapentin is more active than precursor drug in inhibiting abdominal contraction amount.

EXAMPLE F2

- 10 Evaluation of analgesic activity of the compounds of the invention by paw licking test.

Three groups of male Swiss mice (20-25 g, Charles River), 10 animals each, received by oral administration as in Example F1 gabapentin in an amount of 3 mg/kg (17.5 μ m/kg) or the compound of formula (XVA, Example 1), hereinafter NO-gabapentin, in an amount of 3 mg/kg (8.5 μ m/kg) dissolved in saline solution. The control group received an equal volume of saline solution. One hour after administration of the compound solutions, the mice were injected with formalin in the paw (10 μ l).

The formalin injection induced a biphasic reaction. In first phase (phase I, 0-15 minutes) an acute inflammation was observed; in the second phase (phase II, 15-30 minutes) a release of chemical mediators occurred as in neuropathic pain. Within 30 minutes subsequent to formalin injection, in each animal the time in seconds in which the animal licked its paw was recorded. Analysis was carried out in blind.

The results reported in Table 2 are expressed as the entire time in seconds in which paw licking in animals during the first and second phase as defined above was observed.

- 25 The results show that NO-gabapentin is more active than the starting drug in inhibiting paw licking in first phase even though administered at a molar dose corresponding to 50% of gabapentin. For this reason, in second phase NO-gabapentin is less effective.

30 EXAMPLE F3

Evaluation of analgesic activity of the compounds of the invention in animal models of neuropathic pain.

We have tested the antinoceptive effects of compound of formula (XVA, Example 1), hereinafter NO-gabapentin, in the model of neuropathic pain constituted by the chronic constriction injury of the rat sciatic nerve. The parent compound gabapentin has been used as reference drug.

5 The unilateral peripheal mononeuropathy was obtained according to the method described by Bennet GJ and Xie YK, Pain (33) 1988: 87-107. Sample populations ranging from 8 to 12 rats (SD males weighting 250-300g) for condition were used. The antinoceptive effect of the drugs was determined by measuring the vocalization threshold (VTPP) elicited by paw pressure both at the injured and at the controlateral
10 side. The test was performed at day 14 post lesion. All compounds were tested for acute antinoceptive effects. Acute effects were determined within 60 min following a single intraperitoneal (i.p.) injection of the drugs prior to the test.

Each group of the rats received gabapentin at the dose of 30 mg/kg (175 μ moles/kg), or an equimolar dose of NO-gabapentin (175 μ moles/kg), or the same
15 volume of vehicle (Control group). The drugs were dissolved (20 mg/mL) in vehicle containing saline: DMSO: Castor oil (68:8:24).

The results are reported in Table 3 and show that NO-gabapentin was more efficacious than gabapentin.

20

Table 1

Evaluation of gabapentin and NO-gabapentin analgesic activity in experiment F1 (writhing test)

Treatment	Dose (mg/kg)	Contractions number
Controls	—	39
Gabapentin	1	32
NO-gabapentin	1	24
Gabapentin	3	22
NO-gabapentin	3	15
Gabapentin	10	27
NO-gabapentin	10	15

Table 2

Evaluation of gabapentin and NO-gabapentin analgesic activity in experiment F2
(formalin injected in rats paw)

Treatment	Dose ($\mu\text{m/kg}$)	paw licking (sec)	
		Phase I	Phase II
Controls	—	125	185
Gabapentin	17.5	85	30
NO-gabapentin	8.5	50	60

5

Table 3


Evaluation of gabapentin and NO-gabapentin analgesic activity in experiment F3
(model of neuropathic pain)

Time Post-dosing (min)	Vocalization threshold to pressure in the injured paw (VTPP) (grams)		
	Control	gabapentin (175 $\mu\text{moles/kg}$, ip)	NO-gabapentin (175 $\mu\text{moles/kg}$, ip)
0	144 \pm 10	160 \pm 10	153 \pm 10
5	156 \pm 10	165 \pm 23	187 \pm 10
10	162 \pm 14	191 \pm 29	307 \pm 14
20	150 \pm 08	250 \pm 24	325 \pm 08
40	159 \pm 11	266 \pm 26	390 \pm 11
60	150 \pm 09	250 \pm 38	382 \pm 09

10

CLAIMS

1. Nitrooxyderivatives or salts thereof having the following general formula (I)



5 wherein

c0 is 0 or 1;


b0 is 0 or 1, with the proviso that c0 and b0 can not be simultaneously 0;

k0 is 0 or 1;

R is the radical of an analgesic drug for chronic pain;

10 R_{1c} being H or straight or branched alkyl with from 1 to 5 carbon atoms;

K is (CO) or the bivalent radical (1C) having the following formula:



wherein the carbonyl group is bound to T_1 ; R_1 and R'_1 , same or different, are H, C_1 - C_{10} -alkyl, phenyl or benzyl, $-COOR_y$, in which R_y = H, C_1 - C_{10} -alkyl, phenyl, benzyl;

15 $B = -T_B-X_2-T_{BI}-$ wherein

$T_B = (CO)$ or X, in which $X = O, S, NH$;

with the proviso that:

when $b0 = 1$ and $k0 = 0$, then $T_B = (CO)$;


when $b0 = 1$ and $k0 = 1$, being $K = (CO)$, then $T_B = X$ as defined above;

20 $T_{BI} = (CO)$ or (X), wherein X is as defined above;


when $c0 = 0$, then $T_{BI} = -O-$;

X_2 is such a bivalent bridging group such as the corresponding precursor of B, having the formula $Z-T_B-X_2-T_{BI}-Z'$ in which Z, Z' are independently H or OH, is selected from the following compounds:


25 - Aminoacids: L-carnosine (CI), penicillamine (CV), N-acetylpenicillamine (CVI), cysteine (CVII), N-acetylcysteine (CVIII):




(CI)




(CV)



(CVI)




(CVII)




(CVIII)

5


- Hydroxyacids: gallic acid (DI), ferulic acid (DII), gentisic acid (DIII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII), vanillic acid (DVIII), syringic acid (DXI):




(DII)




(DI)




(DIII)




(DV)




(DVI)



(DVII)




(DVIII)



(DXI)

10

- aromatic polyalcohols: hydroquinone (EVIII), methoxyhydroquinone (EXI), hydroxyhydroquinone (EXII), coniferyl alcohol (EXXXII), 4-hydroxyphenethyl alcohol (EXXXIII), p-coumaric alcohol (EXXXIV):



10 C = bivalent radical having the formula $-T_c-Y-$

wherein


$T_c = (CO)$ or X being as defined above;

with the proviso that when $b_0 = 0$ and $k_0 = 1$:

- $T_c = (CO)$ when $K = (1C)$,

15 - $T_c = X$ as defined above when $K = (CO)$; and

Y has one of the following meanings:



wherein:

n_{IX} is an integer of from 0 to 5;

n_{IIX} is an integer of from 1 to 5;


25 R_{TIX} , R_{TIX} , R_{TIX} , R_{TIX} , the same or different, are H or straight or branched C_1 - C_4 -alkyl;

Y³ is a saturated, unsaturated or aromatic heterocyclic ring with 5 or 6 atoms, containing one to three heteroatoms, said heteroatoms being the same or different and selected from nitrogen, oxygen or sulphur;


or Y may be:

- 5 an alkyleneoxy group $-R'O-$ in which R' is straight or branched C_1 - C_{20} or a cycloalkylene with from 5 to 7 carbon atoms, and wherein in cycloalkylene ring one or more carbon atoms can be replaced by heteroatoms and the ring may present side chains of R' type, R' being as defined above;


or one of the following groups:




wherein nf is an integer from 1 to 6;



wherein $R_{1f} = H, CH_3$ and nf' is an integer from 1 to 6;




- 15 wherein n_3 is an integer from 0 to 5 and n_3' is an integer from 1 to 3; or



in which n_3 and n_3' have the meaning mentioned above:

R is the radical of an analgesic drug having formula (II):



wherein:

W is a carbon or nitrogen atom;

m is an integer of from 0 to 2;


$R_0 = H$, $-(CH_2)_n-COOR_y$, R_y being as defined above;

5 n is an integer of from 0 to 2;

$R_1 = H$; when $W = N$, R_1 is the electronic doublet on nitrogen atom (free valence);

R_2 is selected from the following groups:

- phenyl, optionally substituted with a halogen atom or with a group selected from $-OCH_3$, $-CF_3$, nitro;
- 10 - mono or dihydroxy-substituted benzyl, preferably 3,4-dihydroxybenzyl;
- amidino group: $H_2N(C=NH)-$;
- a radical of formula (IIA), wherein optionally an ethylenic unsaturation may be present between the carbon atoms in position 1 and 2, or 3 and 4 or 4 and 5:



15 wherein:

p , p_1 , p_2 are integers, same or different, and are 0 or 1;

p_3 is an integer of from 0 to 10;

R_4 is hydrogen, straight or branched C_1 - C_6 -alkyl, free valence;

R_5 may have the following meanings:

- 20 - hydrogen,
- straight or branched C_1 - C_6 -alkyl,
- C_3 - C_6 -cycloalkyl,
- OR_A , RA having the following meanings:
- straight or branched C_1 - C_6 -alkyl, optionally substituted with one or more
- 25 halogen atoms, preferably F,
- phenyl optionally substituted with a halogen atom or with one of the following groups: $-OCH_3$, $-CF_3$, nitro;

R_6, R_{6A}, R_7, R_8 , the same or different, are H, methyl or free valence, with the proviso that when an ethylenic unsaturation is present between C_1 and C_2 in radical of formula (IIA), R_4 and R_5 are free valences able to form the double bond between C_1 and C_2 ; if the unsaturation is between C_3 and C_4 , R_6 and R_7 are free valence able to form the double bond between C_3 and C_4 ; if the unsaturation is between C_4 and C_5 , R_7 and R_8 are free valence able to form the double bond between C_4 and C_5 ;



Q is H, OH, OR_B , R_B being benzyl, straight or branched C_1 - C_6 -alkyl, optionally substituted with one or more halogen atoms, preferably F, phenyl optionally substituted with a halogen atom or with one of the following groups: $-OCH_3$, $-CF_3$, nitro; or

Q may have one of the following meanings:


- straight or branched C_1 - C_6 -alkyl,
- C_3 - C_6 -cycloalkyl,
- guanidino ($H_2NC(=NH)NH-$),
- thioguanidino ($H_2NC(=S)NH-$).

in formula (II) R_2 with R_1 and with $W = C$ form together a C_4 - C_{10} saturated or unsaturated ring.

- 20 2. Compounds according to claim 1, characterized in that Y^3 in formula (III) is selected from:



(Y19)



5

3. Compounds according to claim 1, characterized in that in formula (I):

c0 is 1;

b0 is 0 or 1;

k0 is 0 or 1;

10 R_{1c} = H;

K is (CO) or the bivalent radical (1C) as defined in claim 1;

B = -T_B-X₂-T_{BI}- wherein

T_B = (CO) or X, in which X = O, S, NH;

with the proviso that:

15 when b0 = 1 and k0 = 0, then T_B = (CO);

when b0 = 1 and k0 = 1, being K = (CO), then T_B = X as defined above;

T_{BI} = (CO) or (X), wherein X is as defined above;

when c0 = 0, then T_{BI} = -O-;

the precursor of B is N-acetylcysteine or ferulic acid;

20 C = bivalent radical having the formula -T_c-Y-

wherein


T_c = (CO) or X being as defined above;

with the proviso that when b0 = 0 and k0 = 1:

- T_c = (CO) when K = (1C),

25 - T_c = X as defined above when K = (CO); and

Y has one of the following meanings:




wherein:

nIX and nIX are 1;


R_{TLX}, R_{TLX}, R_{TLX}, R_{TLX} are H;

10 Y³ is selected from the following bivalent radicals:




or Y may be:

an alkyleneoxy group -R'O- in which R' is straight or branched C₂-C₆ alkyl; or




wherein R_{1f} = H, CH₃ and nf' is an integer from 1 to 4;



wherein n3 is an integer from 0 to 3 and n3' is an integer from 1 to 3;

R is the radical of an analgesic drug having formula (II):



wherein:

W is a carbon atom;

m is 0 or 1;

$R_0 = H$ or $-(CH_2)_n-COOH$, wherein n is an integer of from 0 to 2;

$R_1 = H$;

R_2 is selected from the following groups:

- 5 - 3,4-dihydroxybenzyl; or
 - a radical of formula (IIA) as defined in claim 1, wherein:

p and p_1 are 0 or 1;

p_2 and p_3 are 0;

R_4 and R_5 are hydrogen, straight or branched C_1 - C_6 -alkyl or free valence;

- 10 R_6 and R_{6A} are H;

with the proviso that when an ethylenic unsaturation is present between C_1 and C_2 in radical of formula (IIA), R_4 and R_5 are free valences able to form the double bond between C_1 and C_2 ;

Q is H, CH_3 or

- 15 - guanidino ($H_2NC(=NH)NH-$), or
 - thioguanidino ($H_2NC(=S)NH-$);
 in formula (II) R_2 with R_1 and with W form together a C_6 saturated ring.

4. Compounds according to claims 1-3, wherein when in formula (II) $W = C$,

- 20 $m = 1$ and $R_0 = -(CH_2)_n-COOR_y$, wherein $n = 1$ and $R_y = H$; R_2 and R_1 with W as defined above form the cyclohexane ring; the drug precursor of R having the formula $R-NH_2$ is known as gabapentin;

- when in formula (II) $W = C$, $m = 0$ and R_0 if defined as for gabapentin with $n = 0$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = 1$, $p_2 = p_3 = 0$, $R_4 = R_5$
 25 $= R_6 = R_{6A} = H$, Q = H; the drug precursor of R having the formula $R-NH_2$ is known as norvaline;

- when in formula (II) $W = C$, $m = 0$ and R_0 if defined as for gabapentin with $n = 0$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = 1$, $p_2 = p_3 = 0$, $R_4 = R_5$
 30 $= R_6 = R_{6A} = H$, Q is the guanidino group; the drug precursor of R having the formula $R-NH_2$ is known as arginine;

- when in formula (II) $W = C$, $m = 0$ and R_0 if defined as for gabapentin with $n = 0$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = 1$, $p_2 = p_3 = 0$, $R_4 = R_5$

= $R_6 = R_{6A} = H$, Q is the thioguanidino group; the drug precursor of R having the formula $R-NH_2$ is known as thiocitrulline;

when in formula (II) $W = C$, $m = 1$ and R_0 is defined as for gabapentin with $n = 1$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = p_2 = p_3 = 0$, $R_4 = H$,
 5 $R_5 = Q = CH_3$; the drug precursor of R having the formula $R-NH_2$ is known as pregabalin;

when in formula (II) $W = C$ and has (S) configuration, $m = 1$ and R_0 is defined as for gabapentin with $n = 1$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = p_2 = p_3 = 0$, $R_4 = H$, $R_5 = Q = CH_3$; the drug precursor of R having the formula $R-NH_2$ is known as (S)3-isobutylGABA;
 10

when in formula (II) $W = C$ and has (S), $m = 0$; $R_0 = R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = 1$, $p_2 = p_3 = 0$, $R_4 = R_5 = R_6 = R_{6A} = H$, Q is the guanidino group; the drug precursor of R having the formula $R-NH_2$ is known as agmatine;


when in formula (II) $W = C$, $m = 0$; R_0 is defined as for gabapentin with $n = 2$; $R_1 = H$; R_2 is the radical of formula (IIA) in which $p = p_1 = p_2 = p_3 = 0$, R_4 and R_5 are free valences and between C_1 and C_2 there is an ethylenic unsaturation, $Q = H$; the drug precursor of R having the formula $R-NH_2$ is known as vigabatrin;
 15

when in formula (II) $W = C$, $m = 0$; R_0 is defined as for gabapentin with $n = 0$; $R_1 = H$; R_2 is the 3,4-dihydroxybenzyl radical; the drug precursor of R having the formula $R-NH_2$ is known as 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid (dopa).
 20

5. Compounds according to claims 1-3, wherein the drug precursors of R in formula (I) are selected from lamotrigine, topiramate, zonisamide, carbamazepine, felbamate,
 25 amineptine, amoxapine, demexiptiline, desipramine, nortriptyline, tianeptine.


6. Compounds according to claims 1, 3 and 4 selected from:

1-[4-(nitrooxymethyl)benzoylaminomethyl]-cyclohexaneacetic acid (XVA),



(XVA)


1-[3-(nitrooxymethyl)benzoylamino]methyl-cyclohexaneacetic acid (XVIA),



(XVIA)


5

1-[2-(nitrooxymethyl)benzoylamino]methyl-cyclohexaneacetic acid (XVIIA),



(XVIIA)


1-(4-nitrooxybutanoylamino)methyl-cyclohexaneacetic acid (XVIII A),



(XVIII A)


10

1-(nitrooxymethoxycarbonylamino)methyl-cyclohexaneacetic acid (XIXA),



(XIXA)


1-{{[4-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-cyclohexaneacetic acid (XXA),



5

(XXA)


1-{{[3-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-cyclohexaneacetic acid (XXIA),



10


(XXIA)

1-{{[2-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-cyclohexaneacetic acid (XXIIA),




(XXIIA)

1-[3-(nitrooxymethyl)phenoxy]carbonylaminoethyl]-cyclohexaneacetic acid (XXIII A),




(XXIII A)

5 {2-methoxy-4-[(1E)-3-[4-(nitrooxybutoxy)-3-oxa-1-propenyl]phenoxy]-carbonylaminoethyl}-cyclohexaneacetic acid (XXIV A),




(XXIV A)

3-(S)-[4-(nitrooxymethyl)benzoylaminoethyl]-5-methyl-hexanoic acid (XXV A),




(XXV A)

3-(S)-[3-(nitrooxymethyl)benzoylaminoethyl]-5-methyl-hexanoic acid (XXVI A),




(XXVI A)


3(S)-[2-(nitrooxymethyl)benzoylaminoethyl]-5-methyl-hexanoic acid (XXVIIA),




3(S)-[4-(nitrooxybutanoyl)aminomethyl]-5-methyl-hexanoic acid (XXVIII A),




3(S)-[4-(nitrooxymethoxycarbonyl)aminomethyl]-5-methyl-hexanoic acid (XXIX A),



10 3(S)-{[2-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminoethyl}-5-methyl-hexanoic acid (XXXA),




3(S)-{[3-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-5-methyl-hexanoic acid (XXXIA),




(XXXIA)

5 3(S)-[4-(nitrooxymethyl)benzoyloxy]methoxycarbonylaminomethyl}-5-methyl-hexanoic acid (XXXIIA),





(XXXIIA)

10 3(S)-[(3-nitrooxymethyl)phenoxy]carbonylaminomethyl}-5-methyl-hexanoic acid (XXXIIIA),




(XXXIIIA)

3(S)-{2-methoxy-4-[(1E)-3-[4-(nitrooxybutoxy)-3-oxa-1-propenyl]phenoxy]carbonylaminomethyl}-5-methyl-hexanoic acid (XXXIVA),



(XXXIVA)

1-[4-(nitrooxybutyloxycarbonyl)aminomethyl]-cyclohexaneacetic acid (XXXVA),



(XXXVA)

5

7. Compounds according to claims 1-6, in combination with NO-donor compounds.

8. Compounds according to claim 7, wherein the NO-donors contain in the molecule radicals of the following drugs: aspirin, salicylic acid, ibuprofen, paracetamol, naproxen, diclofenac and flurbiprofen.

10

9. Pharmaceutical compositions comprising compounds according to claims 1-8 as active ingredients.

15

10. Compounds according to claims 1-8 to be employed as a drug.

11. Use of the compounds according to claims 1-8 for preparing drugs for chronic pain.

12. Use of the compounds according to claim 11, wherein the chronic pain is neurophatic pain.

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50932

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C235/42 C07C235/12 C07C271/22 C07C271/54 A61K31/325
A61K31/16 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03/000642 A (NICOX) 3 January 2003 (2003-01-03) claims; examples	1-12
X	WO 97/16405 A (NICOX) 9 May 1997 (1997-05-09) claims; examples	1, 8-12
X	WO 02/11707 A (NICOX) 14 February 2002 (2002-02-14) claims 1, 7	5
X	WO 00/54773 A (NITROMED) 21 September 2000 (2000-09-21) claims 1-3	5, 7
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 May 2004

Date of mailing of the international search report

27/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zervas, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/50932

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 01/90052 A (WARNER-LAMBERT) 29 November 2001 (2001-11-29) page 5, line 9 - line 25; claims; examples</p>	1,9-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/50932

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-4,7-12 (all in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-4,7-12 (all in part)

Present claims 1-4 and 7-12 relate to an extremely large number of possible compounds and their use as pharmaceuticals. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

In addition, present claims 1 and 7 relate to compounds defined by reference to a desirable characteristic, namely "R is the radical of an analgesic drug for chronic pain" (claim 1) and "NO-donor compounds" (claim 7).

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds and drugs as defined in claims 5 and 6.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/50932

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03000642	A	03-01-2003	IT MI20011308 A1 CA 2450538 A1 WO 03000642 A2 EP 1417165 A2	23-12-2002 03-01-2003 03-01-2003 12-05-2004
WO 9716405	A	09-05-1997	IT MI952263 A1 AT 193883 T AU 709338 B2 AU 7495096 A BR 9611175 A CA 2235996 A1 DE 69608916 D1 DE 69608916 T2 WO 9716405 A1 EP 0871606 A1 ES 2148808 T3 GR 3033827 T3 HU 9802986 A2 JP 11514636 T PT 871606 T RU 2165921 C2 SI 871606 T1 US 6040341 A	30-04-1997 15-06-2000 26-08-1999 22-05-1997 30-03-1999 09-05-1997 20-07-2000 11-01-2001 09-05-1997 21-10-1998 16-10-2000 31-10-2000 28-04-1999 14-12-1999 30-11-2000 27-04-2001 31-08-2000 21-03-2000
WO 0211707	A	14-02-2002	IT MI20001848 A1 AU 9169101 A WO 0211707 A2 EP 1307184 A2 US 2003203899 A1	08-02-2002 18-02-2002 14-02-2002 07-05-2003 30-10-2003
WO 0054773	A	21-09-2000	AU 3490300 A WO 0054773 A1	04-10-2000 21-09-2000
WO 0190052	A	29-11-2001	GB 2362646 A AU 6045501 A BR 0111126 A CA 2409768 A1 EP 1284960 A1 WO 0190052 A1 JP 2003534312 T US 2003216469 A1	28-11-2001 03-12-2001 30-12-2003 29-11-2001 26-02-2003 29-11-2001 18-11-2003 20-11-2003